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Constipation can be a significant problem in critically unwell patients, associated with 
detrimental outcomes. Opioids are thought to contribute to the mechanism of bowel 
dysfunction. We tested if methylnaltrexone, a pure peripheral mu-opioid receptor 
antagonist, could reverse opioid induced constipation 
Methods 
The MOTION trial is a multi-centre, double blind, randomised placebo controlled trial to 
investigate whether methylnaltrexone alleviates opioid induced constipation (OIC) in critical 
care patients. Eligibility criteria included adult ICU patients who were mechanically 
ventilated, receiving opioids and were constipated (had not opened bowels for a minimum 
48 hours) despite prior administration of regular laxatives as per local bowel management 
protocol. The primary outcome was time to significant rescue-free laxation. Secondary 
outcomes included gastric residual volume,  tolerance of enteral feeds,  requirement for 
rescue laxatives, requirement for prokinetics, average number of bowel movements per 
day, escalation of opioid dose due to antagonism/reversal of analgesia, incidence of 
ventilator-associated pneumonia, incidence of diarrhoea and Clostridium difficile infection 
and finally 28 day, ICU and hospital mortality. 
Results 
A total of 84 patients were enrolled and randomized (41 to methylnaltrexone and 43 to 
placebo). The baseline demographic characteristics of the two groups were generally well 
balanced. There was no significant difference in time to rescue-free laxation between the 
groups (Hazard ratio 1.42, 95%CI 0.82-2.46, p=0.22). There were no significant differences in 
the majority of secondary outcomes, particularly days 1-3. However, during days 4-28, there 
were fewer median number of bowel movements per day in the methylnaltrexone group, 
(p=0.01) and a greater incidence of diarrhoea in the placebo group (p=0.02). There was a 
marked difference in mortality between the groups, with ten deaths in the 
methylnaltrexone group and two in the placebo group during days 4-28. (p=0.007). 
Conclusion 
We found no evidence to support the addition of methylnaltrexone to regular laxatives for 
the treatment of opioid induced constipation in critically ill patients, however the 





Bowel dysfunction in the intensive care unit (ICU) represents an important problem, with up 
to 70% of patients suffering from constipation [1].  There is increasing evidence that opioids 
contribute to perioperative and ICU bowel dysfunction [2]. Studies have demonstrated that 
bowel dysfunction in the critically ill is associated with adverse outcomes including delay in 
gastric emptying leading to increased gastro-oesophageal reflux and aspiration, decreased 
enteral feeding, delayed ICU discharge and increased mortality [3-5]. Restoration of bowel 
function is beneficial in establishing enteral feeding; it prevents bacterial translocation, 
alleviates gastrointestinal discomfort due to constipation and shortens ICU stay [6]. 
Although bowel dysfunction in ICU patients is multifactorial, both exogenous and 
endogenous opioids do significantly contribute to bowel dysmotility [7].  
Methylnaltrexone is a pure peripheral mu-opioid receptor antagonist.  It is a quaternary 
ammonium compound with a positive charge, which limits its ability to cross the blood-brain 
barrier. Hence, unlike naloxone, methylnaltrexone does not reverse the desired centrally 
mediated effects. The efficacy and safety of methylnaltrexone in the treatment of opioid 
induced constipation have been demonstrated in the palliative care setting [8, 9] with 
significant relief of constipation following administration of subcutaneous 
methylnaltrexone, and no significant changes to pain scores, occurrence of opioid 
withdrawal symptoms or other reported adverse events. 
The Methylnaltrexone for the Treatment of Opioid Induced Constipation & Gastrointestinal 
Stasis in Intensive Care Patients (MOTION) trial was designed to test the efficacy of 
methylnaltrexone in relieving constipation in ICU patients whose sedative regimen included 







The MOTION trial was a multi-centre, double-blind, randomised, placebo-controlled study, 
conducted in the ICUs within Imperial College Healthcare NHS Trust (Hammersmith, Charing 
Cross and St. Mary’s Hospitals) and Queen Elizabeth Hospital King’s Lynn NHS Trust, UK, from 
March 2015 to December 2018, funded by the National Institute for Health Research (NIHR 
PB-PG-0613-31073) and sponsored by Imperial College London. The trial was managed 
(including quality control and data collection) by Imperial Clinical Trials Unit. The full protocol 
was developed by the trial management committee and has previously been published [10]. 
Ethical approval was obtained from the London–Harrow Research Ethics Committee (REC ref 
14 LO 2004, issued 17th December 2014). As patients were sedated and lacked capacity, their 
‘Personal Legal Representative’ (PerLR) or a doctor who was not connected with the conduct 
of the trial, ‘Professional Legal Representative’ (ProLR), gave written consent prior to 
inclusion. Subsequently, written informed consent to continue participation was obtained 
from the patient once capacity was regained. 
The study was overseen by an independent Data Monitoring and Ethics Committee. 
Trial Registration Number: EudraCT reference: 2014-004687-37 
REC reference: 14/LO/2004 
 
Study Population 
Eligibility criteria included adult ICU patients who were mechanically ventilated and 
receiving opioids. Patients were included if they were constipated (defined as absence of 
any stool evacuation) for a minimum 48 hours) despite prior administration of regular 
laxatives as per local bowel management protocol (twice daily 7.5mg senna, Reckitt 
Benckiser Healthcare (UK) Ltd, Slough, UK) having already received at least one dose, and 
scheduled to be enterally fed via nasogastric tube and to receive further opioid analgesics 
for at least 24 hours. Patients were excluded if they presented with diarrhoea, had 
undergone gastro-intestinal tract surgery within 8 weeks prior to ICU admission, showed 
signs of mechanical gastrointestinal obstruction or acute surgical abdomen, had a history of 
inflammatory bowel disease, ileostomy or colostomy, were receiving palliative care (or not 
expected to survive more than 12 hours), had severe chronic hepatic impairment (Child 
Pugh Class C) or encephalopathy, had end-stage renal failure requiring dialysis on admission, 
were known to have hypersensitivity to study drug or any of its excipients, were pregnant, 
or known to have received another trial of an investigational medicinal product within 30 
days or were currently in another interventional trial that might interact with the study drug 
or had previously been enrolled into MOTION. All patients were sedated to facilitate 
mechanical ventilation, with the regimen titrated by the bedside nurse and clinical team to 
the patient’s need and the Richmond Agitation Sedation Score (RASS). The standard 
sedation composed of an opioid (remifentanil, fentanyl or morphine) and a hypnotic agent 




Patients were randomised to either treatment (methylnaltrexone, Salix Pharmaceuticals, , 
Raleigh, North Carolina, USA)) or control group (placebo; saline) on a 1:1 basis, stratified by 
ICU, with randomly selected block sizes of 2 and 4. Randomisation lists were prepared by 
the trial statistician and concealed from all clinical investigators. The treatment group 
received methylnaltrexone (a colourless liquid) dosed as per the Summary of Product 
Characteristics: patients weighing 38–61 kg received 8 mg (0.4 mL) methylnaltrexone diluted 
in 50 mL of 0.9% saline; patients weighing 62–114 kg received 12 mg (0.6 mL) 
methylnaltrexone diluted in 50 mL of 0.9% saline. The control group received placebo 
(saline) prepared in identical syringes to the study drug. Both groups received the blinded 
study drugs over 15 minutes via an indwelling intravenous catheter. An unblinded research 
nurse who was not involved in any clinical management of the patient or any data 
collection, carried out the preparation and administration of study drugs. All clinical staff 
(medical, nursing and pharmacy) as well as patients and relatives remained blinded to 
treatment allocation for the duration of the study. The patient continued to receive the 
study drugs at the same time daily, until the patient was free of opioids for 24 hours or at 28 
days. If a patient allocated to either arm failed to open their bowels within 72 hours of 
receiving study drugs, then rescue laxatives of a combination of sodium picosulfate (5 mg, 
Ferring Pharmaceuticals, West Drayton, UK) and two glycerin suppositories (4 g, Thornton & 
Ross Ltd, West Yorkshire, UK) were administered.  
Outcomes 
The primary outcome was time to significant rescue-free laxation following randomisation. 
Significant laxation was defined as a stool volume of >100 mL, as estimated by the bed-side 
nurse. Secondary outcomes measured on a daily basis whilst receiving the study drugs 
included: gastric residual volume measured every 4 hours and totalled over 24 hours; 
tolerance of enteral feeds (defined by daily assessment of percentage of patients achieving 
full target of enteral feeding); requirement for rescue laxatives; requirement for prokinetics; 
average number of bowel movements per day; escalation of opioid dose due to 
antagonism/reversal of analgesia and sedation; incidence of ventilator-associated 
pneumonia, defined by the Clinical Pulmonary Infection Score (CPIS) and positive 
microbiology blood cultures; incidence of diarrhoea and Clostridium difficile infection 
(polymerase chain reaction or toxin test positive); and finally 28 day, ICU and hospital 
mortality.  
Statistical Methods 
The sample size was estimated for the primary endpoint of time from randomisation 
to rescue-free laxation; this was based on the Phase III trial in palliative care patients where 
48% of subjects receiving Methylnaltrexone had rescue-free laxation within 4 hours 
compared to 15% in the placebo arm, p<0.001 [8]. Pilot data suggested that a difference in 
efficacy of this magnitude would be reasonable in the ICU setting (71% vs. 0% opened 
bowels within 12 hours) [11]. Allowing for a drop-out rate of 5% (patients who withdraw 
consent after regaining consciousness), with 42 subjects in each arm (26 events) this study 
had 85% power to detect a difference of 33% (48% vs, 15%) in the proportion of patients 
with rescue-free laxation within 12 hours at the 5% level (using a two-tailed log-rank test). 
All analyses were on an intention-to-treat basis. Cox regression, stratified by ICU, was used 
to estimate the effect of treatment group on time to rescue-free laxation. Patients who did 
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not achieve rescue free laxation were censored at the date rescue laxatives were given, or, if 
none were given, at 96 hours after randomisation. The appropriateness of the proportional 
hazards assumption was verified by including a term for interaction between treatment 
group and time in the model. Two sensitivity analyses were performed; firstly, the Cox 
regression analysis was repeated with stratification by ICU and adjustment for age, sex, 
APACHE II score, type of opioid and other sedatives and secondly, with stratification by ICU 
and time measured from the when the study drug was started rather than randomisation.  
Secondary outcomes were summarized using basic descriptive methods and presented for 
the placebo and methylnaltrexone groups separately, and in total (further details in 
Supplementary Information). Differences in secondary outcomes between the placebo and 
methylnaltrexone groups were assessed using appropriate hypothesis tests. There was no 
adjustment for multiple testing. Owing to the short observation period, a competing risk 







The trial was completed once the recruitment target of 84 participants had been achieved 
and all participants had been followed up for 28 days post-randomisation. The CONSORT 
diagram (Figure 1) shows the flow of participants in the trial, including the timing and 
reasons given for non-participation and withdrawal from the trial. A total of 84 patients 
were enrolled and randomized (41 to methylnaltrexone and 43 to placebo). Two patients 
withdrew from the methylnaltrexone group (one shortly after randomisation and one on 
Day 1) leaving 39 patients in the methylnaltrexone group and 43 in the placebo group for 
the analysis of primary and secondary outcomes. Patients who withdrew did not allow 




The baseline demographic characteristics of the two groups were generally well balanced 
between the treatment groups (Table 1) although there were more males in the placebo 
group (72%) than in the methylnaltrexone group (65%), and there were differences in mean 
age (58.6 years compared with 55.6 years) and ethnicity (71.8% Caucasian compared with 
58.5% Caucasian) in the placebo and methylnaltrexone groups respectively.  
The clinical characteristics of the two groups are summarised in Table 2. More patients in 
the methylnaltrexone group were admitted for emergency operative procedures (24%) than 
in the placebo group (14%). Most patients were receiving fentanyl at the time of 
randomisation (76%), some remifentanil (19%). Most (83%) were also receiving other 
sedatives. More patients received selective digestive decontamination (SDD) in the placebo 
group (23% vs 10%).  
Details of time in ICU, study treatment, opioids and sedatives received during the study 
period, and protocol violations, are reported in Supplementary Information.  
 
Primary outcome 
Rescue free laxation within 96 hours was achieved in 28/43 (65.1%) of participants in the 
placebo group and 27/39 (69.2%) of participants in the methylnaltrexone group. Kaplan-
Meier curves showing time to rescue free laxation in the placebo and methylnaltrexone 
groups are presented in Figure 2. Cox regression analysis, with stratification by centre/ICU, 
suggested no significant difference in time to rescue free laxation between the groups 
(Hazard ratio 1.42, 95%CI 0.82-2.46, p=0.22). The percentage of participants who had 
experienced rescue free laxation at 4, 12 and 72 hours, and associated 95% confidence 
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intervals, are given for the placebo and methylnaltrexone groups separately, and in total, in 
Figure 2.  Pre-planned sensitivity analyses additionally adjusting for age, sex, APACHE II 
score, type of opioid, other sedatives, and using the date the study drug was first 
administered as the start point rather than date of randomisation, gave very similar results, 
with hazard ratios for treatment with methylnaltrexone relative to placebo of 1.46 (95% CI 
0.82-2.61) and 1.37 (95% CI 0.79-2.38) respectively. For all the Cox models, the proportional 
hazards assumption appeared valid.   
 
Secondary outcomes 
The key secondary outcomes are summarised in Table 3.  There was no significant 
difference in median number of bowel movements per day between the placebo and 
methylnaltrexone groups on days 1-3 (p=0.58, Wilcoxon test) but the difference over days 4-
28 was statistically significant (p=0.01, Wilcoxon test) with fewer bowel movements per day 
reported in the methylnaltrexone group. There was no significant difference in the number 
of diarrhoea-related adverse events between the placebo and methylnaltrexone groups (11 
vs 8; P=0.61, Chi-squared test) but diarrhoea was significantly more frequent in the placebo 
group compared to the methylnaltrexone group (p=0.02; Pearson’s Chi-squared test). The 
number of bowel movements per patient per day involving diarrhoea during days 1-3 was 
similar in the placebo and methylnaltrexone groups (p=0.27, Wilcoxon test) but significantly 
different during days 4-28 (p=0.03, Wilcoxon test).    
Further details of other secondary outcomes are given in Supplementary Table 3. These 
include changes in opioid dose between baseline and 4 hours, gastric residual volume 
achieved, the proportion of patients achieving full enteral feed, the number of patients 
requiring metoclopramide, erythromycin, increasing doses of opioids, the number of 
patients developing ventilator-associated pneumonia, the number of patients with positive 
microbiology cultures and the number of patients who died. There was a marked difference 
in mortality between the methylnaltrexone and placebo groups. Ten deaths were reported 
in the methylnaltrexone group and two in the placebo group during the 28 day follow up 
period. Post-hoc survival analyses showed that this difference was statistically significant 
(p=0.007, log rank test). The corresponding Kaplan-Meier survival curves are shown in 
Supplementary Figure 1. There were no deaths within the first 3 days (72 hours) and none 
occurred prior to the primary endpoint being observed. Clinical records of the deceased 
participants were reviewed and the UK Medicines and Healthcare Related Products 
Authority informed, but there was no indication that the difference was study drug related. 
We therefore performed a number of post-hoc Cox-regression analyses to investigate 
whether the observed difference in survival might be explained by differences in baseline 
risk of death, assessed using the following measures: original APACHE II risk of death, 
APACHE UK 2013, APACHE UK 2015, ICNARC model 2013, ICNARC model 2015 and SAPSII 
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score. The expected number of deaths in each treatment group is reported in 
Supplementary Table 7 with estimates ranging from 12.38 to 15.30 for the placebo group 
and from 11.34 to 14.61 in the methylnaltrexone group.  The number of observed deaths in 
both treatment groups was less than expected but the discrepancy was far greater in the 
placebo group.    Adjustment for age, sex, centre, reason for admission to ICU (medical or 
surgical) in addition to baseline risk of death (whichever method/score used) did not explain 
the observed difference in survival between the treatment groups. 
 
Safety 
Protocol reporting time-frames for adverse events were from the time of informed consent 
until discharge from ICU or for a maximum of 28 days. Adverse events are summarised in 
Table 3 and further details given in Supplementary Table 6. There was little difference 
between the methylnaltrexone and placebo groups as regards to frequency of adverse and 
serious adverse events but diarrhoea, which was mild to moderate in all cases, was more 
common in the placebo group than in the methylnaltrexone group (11 vs 8). None of the 








In this multi-centre, double-blind, randomised, placebo-controlled trial in critical care patients 
with opioid induced constipation, the addition of methylnaltrexone to regular laxatives had 
no additional benefit but the confidence interval was wide, consistent with there being 
between 18% less and two and a half times more chance of rescue free laxation in those on 
methnaltrexone compared to placebo. Thus, a clinicially important difference cannot be 
excluded. There were also no clear benefits in gastric residual volume; tolerance of enteral 
feeds; requirement for rescue laxatives; requirement for prokinetics; incidence of ventilator-
associated pneumonia or bacteraemia; or mortality at any time point. Intravenous 
methylnaltrexone was well tolerated with no drug related significant adverse effects, and no 
evidence of increased opioid requirements suggesting that it did not cross the blood brain 
barrier and antagonise the desired central opioid effects. 
The baseline demographic characteristics of the two groups were generally well matched 
other than some minor imbalances in gender, age and ethnicity which would be anticipated 
in a relatively small trial (Table 1). There were some differences in clinical characteristics, most 
notably more patients in the methylnaltrexone group were admitted for emergency operative 
procedures (24%) than in the placebo group (14%), and more patients received selective 
digestive decontamination (SDD) in the placebo group (23% vs 10%). It was also noteworthy 
that there was greater incidence of subsequent diarrhoea in the placebo group than in the 
methylnaltrexone group (11 patients vs 8 patients). We speculated post hoc that SDD may 
have had an impact and we explored for this in a sensitivity analysis (Supplement) but found 
no evidence of an effect. 
While strong evidence supports the use of methylnaltrexone in palliative care patients with 
opioid induced constipation [8, 9], this is the first study investigating its use in critical care. 
The absence of any beneficial effect is surprising given our group’s exploratory study [11], 
which suggested that methylnaltrexone was more effective as rescue therapy for established 
constipation than sodium picosulphate. In critical care patients, high dose enteral naloxone 
has been shown to decrease gastric residual volume and reduce ventilator associated 
pneumonia rates [12] and this provided further encouragement that similar results could be 
achieved with methylnaltrexone. 
There are a number of potential factors that may account for our findings. During the course 
of the “gestation” period for this study, attitudes to managing sedation had been evolving 
and it is conceivable that clinical staff were targeting lighter levels of sedation for most 
patients. The practice of daily sedation holds has become more established [13] thus reducing 
the duration of significant opiate dosing. 40% of patients were off opioids or receiving 
prolonged sedation holds on Day 2, hence the impact of opioids on constipation and the 
advantage of reversing this specifically with an opioid antagonist is diminished.   Constipation 
in critical care patients is multifactorial, but the opioid component over time may have 
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become less significant. The pre-trial levels of constipation which we had anticipated in the 
placebo group, based on our previous work, did not materialise. In fact, the placebo group 
had a higher incidence of subsequent diarrhoea and passed more stools. Possibly the 
increased attention on bowel function and protocolised prescriptions (all patients received 
senna prior to enrolment) had a major impact on the placebo arm event rate, thus 
undermining the assumptions on which the trial had been planned and the sample size 
calculated.  
The estimated anticipated treatment effect size came from a study set in palliative care [8], 
the entry criteria for which included two weeks of prior opiate treatment and the failure of 
three days of laxative treatment.  Although our pilot data echoed the clear positive effects 
seen in the palliative care setting, it is possible that the difference in patient groups was 
important and that the theoretical advantages of antagonising opioid receptors [14] in 
patients with cancer in the palliative care studies, do not apply to critical care.  Other patient 
factors that may influence constipation in critically ill patients, such as the presence of 
diabetes gastropathy, level of sedation and pain scores for the duration of the study may have 
provided additional valuable information.    
The apparent excess of deaths in the methylnaltrexone arm is potentially concerning but 
appears to represent a lower than anticipated number of deaths (beyond 96 hours) in the 
placebo arm, rather than an excess in the methylnaltrexone arm. Mortality in both arms was 
less than predicted from baseline risk scores. Neither detailed review of the data captured in 
the study database and clinical records or adjustment for baseline characteristics in the 
survival models, explained the observed difference in mortality between the treatment 
groups. There was also no difference in the rates of serious adverse events between the 
groups. It may therefore be that the imbalance between the trial arms occurred by chance, 
owing to the relatively small trial size.  
Our understanding of the impact and management of constipation and gastro-intestinal tract 
dysfunction is increasing [15]. Despite the above limitations the study has important design 
strengths. It was double-blinded and placebo-controlled, randomisation was concealed, and 
measured patient centred outcomes. The sample size calculations used the best available 
evidence at the time of trial planning. It is conceivable that with the current zeitgeist being 
for more awake patients and with a focused and consistently delivered nutrition and bowel 






We found no evidence to support the addition of methylnaltrexone to regular laxatives for 
the treatment of opioid induced constipation in critically ill patients, however the 
confidence interval was wide and a clinically important difference cannot be excluded.  
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Take Home Message 
Opioid induced constipation can be a significant problem in critically unwell patients, 
associated with detrimental outcomes.  
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The MOTION trial is a multi-centre, double blind, randomised placebo controlled trial to 
investigate whether methylnaltrexone, a pure peripheral mu-opioid receptor antagonist, 
alleviates opioid induced constipation.  
The results of this study do not support the addition of methylnaltrexone to regular 
laxatives for the treatment of opioid induced constipation in critically ill patients. 
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SUPPLEMENTARY INFORMATION  
Trial conduct 
Enrolment, randomisation and data collection were performed by means of InForm (Oracle, 
California, USA), the study’s electronic data capture system. There were 30 protocol 
deviations (summarized in Supplementary Table 5); 16 (relating to 15 participants) in the 
methylnaltrexone group and 14 (relating to 13 participants) in the placebo group, most 
commonly early administration of rescue enema or suppository (<72 hours) (8/30, 27%). 
 
Statistical analysis 
The proportion of patients in each group who received rescue laxatives were compared by 
Pearson’s chi-squared. The median number of bowel movements per day between groups 
was compared using the Wilcoxon test. The daily percentage of patients fulfilling target 
enteral feed (averaged over days in the period) was calculated by counting one for each day 
on which each patient achieved full target enteral feed and averaging for each patient over 
two periods; days 1-3 (approximately the period prior to protocol rescue laxatives time 72 
hours) and days 4-28 (or discharge from ICU if sooner). The incidence of ventilator 
associated pneumonia (VAP) was assessed using the Clinical Pulmonary Infection Score 
(CPIS).  Where an investigation that feeds into the CPIS was not done, the result from the 
previous day was used if available, otherwise the score for that component of the score was 
set to zero. For body temperature and leukocyte count, where more than one value may be 
given, the value giving rise to the most severe score was used. Patients with CPIS scores 
greater than 6 were considered to have a VAP.  The number of adverse events described as 
diarrhoea were compared between the placebo and methylnaltrexone groups using Fisher’s 
exact test. The difference in median number of patients experiencing diarrhoea at least 
once, median number of bowel movements reported to be diarrhoea, and median number 
of bowel movements with diarrhoea per patient per day in the placebo and 
methylnaltrexone groups were compared using Wilcoxon tests. The incidence of Clostridium 
difficile infection (measured by PCR or toxin positive) will be compared in the two groups 
using Fisher’s exact test.  The incidence of positive microbiology blood cultures were 
compared in the two groups using Fisher’s exact test.   
 
Primary outcome 
Of the 15 participants in the placebo group, in which rescue free laxation by 96 hours was 
not achieved, 13 achieved laxation following rescue on Day 5 onwards and 2 had not 
achieved laxation by the end of the follow up period/date of censoring. Of the 12 in the 
methylnaltrexone group who did not achieve rescue free laxation by 96 hours, 13 laxated 
following rescue (Day 5 onwards) and 2 had not achieved laxation by the end of the follow 
up period/date of censoring. 
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Time in ICU, study treatment, opioids and sedatives received during the study period 
The median number of days in ICU, measured from randomisation to a maximum of 28 days, 
was 17 (95% CI 13-21) days in the placebo group and 12 (95% CI 8-18) days in the 
methylnaltrexone group. The study drug was started on the same day as randomisation for 
37/39 (94.87%) in the methylnaltrexone group and 43/43 (100%) in the placebo group. The 
remaining 2 were started on the study drug on the day after randomisation. The median 
number of doses of study drug given in the placebo group was 5 (IQR 2-9) and in the 
methnaltrexone group 4 (2-6). The median number of days on the study drug in ICU, 
measured from randomisation to a maximum of 28 days, was 6 (95% CI 4-8) days in the 
placebo group and 4 (95% CI 3-6) days in the methylnaltrexone group. The median number 
of days from admission to ICU to starting of study drug was 3 (IQR 2-5) in the placebo group 
and 3 (IQR 2-4) in the methylnaltrexone group. The median numbers of days, post-
randomisation, on opioids was 9 (IQR 5-15) in the placebo group and 5 (IQR 4-13) in the 
methylnaltrexone group. Two participants in the methylnaltrexone group received no 
opioids post-randomisation. Details of the type of opioid given and duration are given in 
Supplementary Table 2. As at baseline, fentanyl was more commonly used in the placebo 
group on Day 1 (79% hours 1-4, 79% > 4 hours) than in the methylnaltrexone group (67% 
hours 1-4, 69% > 4 hours). Conversely, remifentanil was used less frequently in the placebo 
group on Day 1 (14% hours 1-4, 16% > 4 hours) than in the methylnaltrexone group (23% 
hours 1-4, 23% >4 hours). There was little difference between the treatment groups in type 
of opioid used from Day 2 onwards. Details of the other sedatives given on Day 1 and the 
number of participant days where other sedatives were given are summarized in 
Supplementary Tables 3 and 4. There was little difference in the proportion of participants 
receiving other sedatives on Day 1 (79% in the placebo group and 82% in the 
methylnaltrexone group), with the majority being given propofol or midazolam, either singly 
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Figure 1 CONSORT diagram showing participant flow through the MOTION trial 
 
 
Total Screened (n=619) Excluded (n=535)
 Ineligible (n=373)a
 Clinical decision (n=46)
 Consent issues (n=22)
 Declined (n=76)





Allocated to Placebo 
(n=43)
Withdrew consent (n=2)
 Prior to receiving at 
least one dose of 
Methylnaltrexone 
(n=1)
 After receiving at 




 Prior to receiving at 
least one dose of 
Methylnaltrexone 
(n=0)
 After receiving at 




Available for analysis of 
primary outcome (n=39)
Available for analysis of 
primary outcome (n=43)
l r Excluded (n=535)
 I li i l  ( )
a
li i
 t i  (n 22)
 eclined (n=76)
 Research nurse not available (n=17)
 Unknown (n=1)
Withdrew consent (n=2)
 Prior to receiving at 
least one dose of 
thylnaltrexone 
 ft r rec iving at 




 Prior to receiving at 
least one dose of 
thylnaltrexone 
 ft r rec iving at 




pri  t e ( = )
 
 
 Footnote: a The most common reasons for ineligibility were: Patient had opened bowels before 
consent could be obtained (N=144); patient had not been prescribed further opioids (N=47); patient 
had bowel obstruction, colostomy or ileostomy (N=28); patient had gastro-intestinal tract surgery 
within previous 8 weeks (N=27); patient was receiving palliative care or was not expected to survive 
more than 12 hours (N=21); patient had end-stage renal failure requiring dialysis on admission 
(N=20); patient was on total parenteral nutrition (N=17); patient had diarrhoea (N=13) or severe 












The percentage of participants who had achieved rescue-free laxation at 4 hours post-randomisation 
was in the methylnaltrexone group was 15.4% (95% CI: 7.2%, 31.1%) and 7.0% (2.3%, 20.1%) in the 
placebo group. At 12 hours post-randomisation the percentage achieving rescue-free laxation had 
increased to 25.6% (95% CI: 14.7%, 42.4%) and 16.5% (8.2%, 31.5%) in the methylnaltrexone and 
placebo groups respectively. By 72 hours post-randomisation the percentage achieving rescue-free 
laxation had increased to 77.8% (60.3%, 91.4%) and 60.0% (45.1%, 75.3%) in the methylnaltrexone 
and placebo groups respectively.  
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Gender [N (%)]    
Female 14 (34.2) 12 (27.9) 26 (31.0) 
Male 27 (65.9) 31 (72.1) 58 (69.0) 
Age  [Mean (SD)] 55.6 (14.8) 58.6 (17.3) 57.1 (16.1) 
BMI (kg/m2) [Median (IQR)]    
Females 25.4 (22.0, 29.5) 24.3 (22.7, 34.8) 25.0 (22.5, 33.6) 
Males 24.5 (23.1, 29.4) 25.3 (22.7, 27.7) 24.7 (22.9, 27.8) 
Ethnicity [N(%)]    
Caucasian 24 (58.6) 28 (71.8) 52 (61.8) 
Asian 12 (29.3) 9 (23.1) 21 (25.0) 
Black 3 (7.3) 2 (5.1) 5 (6.0) 
Other white or white background 1 (2.4) 0 (0.0) 1 (1.2) 






Table 2: Reasons for participant admission to the intensive care unit, type of opoid and other 







Reason for ICU admission [N(%)]a    
Medical (Non-operative) 31 (75.6) 34 (79.1) 65 (77.4) 
Surgical – emergency (operative) 10 (24.4) 6 (14.0) 16 (19.0) 
Surgical – elective (operative) 0 (0.0) 3 (7.0) 3 (3.6) 
    
Type of opioid [N(%)]b    
Fentanyl 29 (70.7) 35 (81.4) 64 (76.2) 
Remifentanil 9 (22.0) 8 (18.6) 17(20.2) 
Morphine 2 (4.9) 0 (0.0) 2 (2.4) 
None 1 (2.4) 0 (0.0) 1 (1.2) 
    
Patients receiving other sedativesc 
[N(%)] 
34 (82.9) 36 (83.7) 70 (83.3) 
Patients receiving vasoactive drugsc 
[N(%)] 
25 (60.9) 27 (62.8) 52 (61.9) 
Patients receiving any muscle relaxant 
[N(%)] 
6 (14.6) 5 (11.6) 11 (13.1) 
Patients receiving Selective Digestive 
Decontamination (SDD) (N=84) 
4 (9.8) 10 (23.3) 14 (16.7) 
PaO2/FiO2 ratio (mmHg) (N=84) 
[Median (IQR)] 
223 (182, 322) 262 (158, 329) 236 (171, 326) 
Patient has moderate or severe ARDS 
(N=84) 
2 (4.9) 4 (9.3) 6 (7.1) 
Creatinine (µmol/L) (N=74) [Median 
(IQR)] 
63.5 (55.0, 111.0) 68.5 (56.5, 103.5) 64.5 (55.0, 106.0) 
Renal replacement therapy (N=84) 4 (9.8%) 4 (9.3%) 8 (9.5%) 
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Bilirubin (µmol/L) (N=73) [Median 
(IQR)] 
13.5 (7.0, 23.0) 10.0 (5.0, 24.0) 13.0 (6.0, 24.0) 
Richmond Agitation Sedation Score 
(N=83) [Median (IQR)] 
-5.0 (-5.0, -4.0) -4.0 (-5.0, -4.0) -5.0 (-5.0, -4.0) 
Patient has traumatic brain injury 
[N(%)](N=84) 
8 (19.5) 7 (16.3) 15 (17.9) 
Total APACHE II score (N=84) [Median 
(IQR)] 
 
20.0 (13.0, 23.0) 
 
16.0 (14.0, 22.0) 
 
17.0 (13.5, 22.0) 
 
Footnote: a Full details of reason for ICU admission are given in Supplementary Table 1; b Further 
details of the opioids received after administration of study drug are given in Supplementary Table 2; 
cFurther details of sedatives and vasoactive drugs received are given in Supplementary Tables 3 and 













Number of patients requiring rescue laxatives (at 
least once) [N (%)] 
17 (43.6) 17 (39.5) 0.74a 
Number of bowel movements per day [Median 
(IQR)] 
   
 Days 1-3  0.67 (0.00, 1.00) 0.67 (0.00, 1.67) 0.58b 
 Days 4-28 1.38 (1.00, 2.00) 2.00 (1.54, 2.50) 0.01b 
    
Diarrhoea reported as adverse event [N (%)] 8 (20.0) 11 (25.6) 0.61c 
Number (proportion) of patients with diarrhoea at 
least once 
23 (59.0%) 36 (83.7%) 0.02a 
Number (proportion) of bowel movements with 
diarrhoea 
208 (23.3%) 336 (23.6%) 0.69a 
    
Number of bowel movements with diarrhoea per 
day [Median, IQR] 
   
Days 1 to 3 0.2 (0.0; 0.0-0.3) 0.4 (0.0; 0.0-0.3) 0.27b 
Days 4 to 28 0.3 (0.0; 0.0-0.4) 0.4 (0.4; 0.1-0.6) 0.03b 
    
Number of patients (%) with clostridium difficile 
infection (PCR or Toxin positive) 
3 (7.7) 7 (16.3) 0.32c 
Number of patients (%) with positive 
microbiology blood cultures  
19 (48.7) 27 (62.8) 0.27c 
Number of patients (%) experiencing adverse 
eventsd 
9 (23.1) 13 (31.7) 0.62c 
Number of patients (%) experiencing serious 
adverse eventsd 
2 (5.1) 2 (4.7) 0.65c 
 
Footnote: a Pearson’s chi squared test; b Wilcoxon test (two-sided); c Fisher’s exact test;d All were 
expected and not related to the study treatment. Further details of secondary outcomes and 














Reason for ICU admission (N=84)    
Medical (Non-operative) 31 (75.6%) 34 (79.1%) 65 (77.4) 
Respiratory 10 7 17 
Post cardiac arrest 7 5 12 
Head injury 4 3 7 
Multiple trauma 2 3 5 
Infection 0 4 4 
Neurologic 0 4 4 
Cardiovascular 2 0 2 
Drug overdose 1 1 2 
Haemorrhage (ICH/ SDH/ SAH) 2 0 2 
Post respiratory arrest 0 2 2 
Seizure disorder 2 0 2 
Aspiration / Poisoning / Toxic 1 0 1 
COPD 0 1 1 
Cardiogenic shock 0 1 1 
Gastrointestinal 0 1 1 
Neoplasm 0 1 1 
Rhythm disturbance 0 1 1 
    
    
Surgical – emergency (operative) 10 (24.4%) 6 (14.0%) 16 (19.0%) 
Cardiovascular 3 2 5 
Craniotomy for ICH/ SDH/ SAH 4 0 4 
Multiple trauma 1 2 3 
Head trauma 1 0 1 
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Heart valve surgery 0 1 1 
Neurologic 0 1 1 
Respiratory 1 0 1 
    
Surgical – elective (operative) 0 (0.0%) 3 (7.0%) 3 (3.6%) 
Heart valve surgery 0 1 1 
Respiratory 0 1 1 






Supplementary Table 2: Type of opioids received after administration of study drug 
 






Day 1: Four hours after study drug    
Fentanyl 26 (66.7) 34 (79.1) 60 (73.2) 
Remifentanil 9 (23.1) 6 (14.0) 15 (18.3) 
Morphine 1 (2.6) 0 (0.0) 1 (1.2) 
No opioid 3 (7.7) 3 (7.0) 6 (7.3) 
    
Day 1: After 4 hours    
Fentanyl 27 (69.2) 34 (79.1) 61 (74.4) 
Remifentanil 9 (23.1) 7 (16.3) 16 (19.5) 
Morphine 1 (2.6) 0 (0.0) 1 (1.2) 
No opioid 2 (5.1) 2 (4.7) 4 (4.9) 
    
Days 2 onwards (patient days)    
Fentanyl 230 (44.1) 346 (47.7) 576 (46.2) 
Remifentanil 54 (10.3) 56 (7.7) 110 (8.8) 
Morphine 9 (1.7) 0 (0.0) 9 (0.7) 
Fentanyl and remifentanil 7 (1.3) 10 (1.4) 17 (1.4) 





Supplementary Table 3: Sedatives and vasoactive drugs received during the study 
 Methylnaltrexone Placebo Total 
Number of patients receiving other 
sedatives at entry to the study 
   
Propofol 24 (58.5) 23 (53.5) 47 (56.0) 
Midazolam 21 (51.2) 15 (34.9) 36 (42.9) 
Clonidine 0 (0.0) 4 (9.3) 4 (4.8) 
Dexmedetomidine 1 (2.4) 0 (0.0) 1 (1.2) 
Ketamine 0 (0.0) 1 (2.3) 1 (1.2) 
None 7 (17.1) 7 (16.3) 14 (16.7) 
Number of patients receiving other 
sedatives on Day 1 of the study  
   
Propofol 22 (56.4) 22 (51.2) 44 (53.7) 
Midazolam 20 (51.3) 14 (32.6) 34 (41.5) 
Clonidine 1 (2.6) 4 (9.3) 5 (6.1) 
Dexmedetomidine 1 (2.6) 0 (0.0) 1 (1.2) 
Ketamine 0 (0.0) 1 (2.3) 1 (1.2) 
None 7 (17.9) 9 (20.9) 16 (19.5) 
Number of patients receiving vasoactive 
drugs at entry to the study [N(%)] 
   
Noradrenaline 22 (53.7) 23 (53.5) 45 (53.6) 
Vasopressin 2 (4.9) 1 (2.3) 3(3.6) 
Adrenaline 1 (2.4) 0 (0.0) 1 (1.2) 
Dobutamine 0 (0.0) 1 (2.3) 1 (1.2) 
Glyceryl trinitrate 1 (2.4) 0 (0.0) 1 (1.2) 
Metaraminol 0 (0.0) 1 (2.3) 1 (1.2) 
Labetalol 0 (0.0) 1 (2.3) 1 (1.2) 
Hydralazine 0.(0.0) 1 (2.3) 1 (1.2) 
Other 3 (7.3) 2 (4.7) 5 (6.0) 
None 16 (39.0) 16 (3.7) 32 (38.1) 
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Total (no. of patients)a 41 43 84 




Supplementary Table 4: Other sedatives given during the study period 







Propofol 182 (33.0) 254 (33.0) 436 (33.0) 
Midazolam 149 (27.0) 156 (20.0) 305 (23.0) 
Clonidine 46 (8.0) 48 (6.0) 94 (7.0) 
Dexmedetomidine 33 (6.0) 47 (6.0) 80 (6.0) 
Other 1 (0.0) 28 (4.0) 29 (2.0) 
None 238 (43.0) 319 (41.0) 557 (42.0) 
Total (Number of patient days) 560 769 1,329 
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Supplementary Table 5: Summary of protocol deviations during the study  






Randomised under wrong site 2 0 2 
Blood samples taken at the wrong time 2 4 6 
Enema given within 72 hours 3 2 5 
Suppositories or lactulose given <72 hours 5 3 8 
Study drug related <72 hours 1 2 3 
Other not related to study drug or treatment <72 hours 3 3 6 
Total 16 14 30 
arelating to 15 participants 









Number of patients requiring more than 1 dose of 
rescue laxatives required [N (%)] 
9 (23.1%) 11 (25.6%) 
Number of times rescue laxative given per patient 
[Mean (SD)] 
1.03 (1.69) 1.02 (1.73) 
Gastric Residual Volume (mls) [Median (IQR)] 0.0 (0.0-40.0) 0.0 (0.0-25.0) 
Full Enteral Feed achieved [Proportion of patient 
days (%)] 
174/531 (32.9%) 225/707 (31.8%) 
Number of patients requiring metoclopramide at 
least once during ICU stay [N (%)] 
15 (38.5%) 13 (30.2%) 
Number of days metoclopramide required (in 
patients requiring metoclopramide at least once) 
[Median (IQR)] 
3 (2-5) 6 (4-10) 
Number of patients requiring erythromycin at 
least once during ICU stay [N (%)] 
10 (25.6%) 7 (16.3%) 
Number of days erythromycin required (in 
patients requiring erythromycin at least once) 
[Median (IQR)] 
6 (3-8) 5 (3-8) 
   
Number receiving fentanyl at baseline [N (%)] 28 (71.8) 35 (81.4%) 
Number receiving fentanyl at 4 hours [N (%)] 26 (92.9) 33 (94.3%) 
 With reduced dose 1 (3.8%) 0 (0.0%) 
 No change in dose 22 (84.6%) 30 (90.9%) 
 Dose increase < 100% 0 (0.0%) 3 (9.1%) 
 Dose increase ≥100% 3 (11.5%) 0 (0.0%) 
   
Number receiving remifentanil at baseline [N 
(%)] 
9 (23.1%) 7 (16.3%) 
Number receiving remifentanil at 4 hours [N (%)] 9 (100%) 5 (71.4%) 
 With reduced dose 3 (33.3%) 0 (0.0%) 
 No change in dose 3 (33.3%) 3 (60.0%) 
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 Dose increase < 100% 1 (11.1%) 1 (20.0%) 
 Dose increase ≥100% 0 (0.0%) 1 (20.0%) 
 Unknown 2 (22.3%) 0 (0/0%) 
   
Clinical Pulmonary Infection Score (CPIS) > 6 [N 
(%)] 
  
 Baseline 11 (26.8) 10 (23.3) 
 Day1 12 (30.8) 9 (20.9) 
 Day 4 13 (35.1) 16 (37.2) 
 Day 7 
 
14 (48.3) 14 (35.9) 
Number of deaths within 28 days of ICU 
admission 
10 2 
Number of patients (%) experiencing adverse 
events whilst receiving study druga 
9 (23.1) 13 (31.7) 
 Diarrhoea (mild/moderate) (%) 8 (20.5) 11 (26.8) 
 Skin rash (mild/moderate) (%) 1 (2.6) 0 (0.0) 
              Respiratory (severe) (%) 2 (5.1) 0 (0.0) 
 Cardiovascular/circulatory (severe) (%) 0 (0.0) 1 (7.7) 
 Digestive/gastrointestinal (severe) (%) 0 (0.0) 1 (7.7) 
 
a All were expected and not related to the study treatment. 
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Supplementary Table 7: Expected number of deaths in the placebo and methylnaltrexone groups 
calculated from individual risk scores at baseline/entry to the trial 
Risk score Expected no. of Deaths 
Methylnaltrexone 
(N=39)(Observed number of 
deaths=10) 
Expected no. of Deaths 
Placebo (N=43)(Observed number 
of deaths=2) 
Knaus 14.61 15.60 
Apache 2013 11.50 13.54 
Apache 2015 11.54 12.38 
ICNARC model 2013 11.34 13.70 
ICNARC model 2015 11.98 14.34 
SAPSII 11.43 12.51 
 

























QEH King’s Lynn 1 (2.4) 1 (2.3) 2 (2.4) 
Total 41 43 84 
 
Supplementary Table 9: Baseline opioid doses prior to enrollment 
 Methylnaltrexone Placebo All 
Fentanyl dose (mcg/h)    
N 29 35 64 
Mean 137.1 142.1 139.8 
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Median (IQR) 100 (100, 200) 150 (100, 200) 100 (100,200) 
    
Remifentanil dose (mcg/h)    
N 9 7 16 
Mean 438.2 213.0 339.7 
Median (IQR) 480 (292, 684) 158 (96, 301) 296 (111, 593) 
 
Supplementary Table 10: Days on study treatment (Methylnaltrexone or placebo) 
 






1 to 3 15 (38.5%) 13 (30.2%) 28 (34.1%) 
4 to 7 15 (38.5%) 11 (25.6%) 26 (31.7%) 
8 to 14 7 (17.9%) 14 (32.6%) 21 (25.6%) 
15 to 21 1 (2.6%) 3 (7.0%) 4 (4.9%) 
22 to 28 1 (2.6%) 2 (4.7%) 3 (3.7%) 
Total patients 39 43 82 
Median (IQR) 4.0 (3.0, 7.0) 6.0 (3.0, 10.0) 5.0 (3.0, 9.0) 
 
Supplementary Table 11: Number of days on opioids 








0 2 (5.1%) 0 (0.0%) 2 (2.4%) 
1 to 3 7 (17.9%) 5 (11.6%) 12 (14.6%) 
4 to 7 13 (33.3%) 11 (25.6%) 24 (29.3%) 
8 to 14 9 (23.1%) 16 (37.2%) 25 (30.5%) 
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15 to 21 6 (15.4%) 6 (14.0%) 12 (14.6%) 
22 to 28 2 (5.1%) 5 (11.6%) 7 (8.5%) 
Total patients 39 43 82 
Median (IQR) 5.0 (4.0, 13.0) 9.0 (5.0, 15.0) 8.0 (4.0, 13.0) 
 
 
